Skip to main content

Advertisement

Table 1 Clinical and laboratory characteristics as well as overall survival of the 305 patients with stage I–II gastric cancer after resection

From: Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage I–II gastric cancer

Characteristic Patients [cases (%)] Overall survival (months)a P b
Age <0.001
 <60 years 168 (55.1) 132.6 (123.7–141.5)  
 ≥60 years 137 (44.9) 110.5 (98.2–122.9)  
Sex 0.072
 Male 202 (66.2) 115.7 (105.6–125.8)  
 Female 103 (33.8) 135.0 (123.7–146.3)  
Tumor location in the stomach <0.001
 Upper third 87 (28.5) 82.0 (70.6–93.4)  
 Middle third 59 (19.3) 131.7 (116.4–147.1)  
 Lower third 159 (52.1) 133.3 (123.3–143.3)  
Tumor size 0.343
 <3 cm 156 (51.1) 123.3 (112.8–133.9)  
 ≥3 cm 149 (48.9) 121.5 (110.4–132.6)  
TNM stage 0.001
 IA 56 (18.4) 108.1 (102.4–113.8)  
 IB 53 (17.4) 112.9 (100.5–125.3)  
 IIA 50 (16.4) 115.9 (98.2–133.6)  
 IIB 146 (47.9) 111.1 (99.0–123.2)  
mGPSc <0.001
 0 158 (51.8) 75.1 (70.5–79.6)  
 1 44 (14.4) 67.4 (58.9–75.9)  
 2 13 (4.3) 42.7 (25.8–59.6)  
PNI 0.010
 0 282 (92.5) 126.7 (118.8–134.7)  
 1 23 (7.5) 68.5 (49.7–87.4)  
PLT–NLR 0.009
 0 210 (68.9) 128.3 (119.9–136.7)  
 1 78 (25.6) 93.7 (79.5–107.8)  
 2 17 (5.6) 125.3 (96.2–154.4)  
NLR–PLR <0.001
 0 120 (39.3) 142.2 (133.7–150.8)  
 1 96 (31.5) 119.0 (105.5–132.5)  
 2 89 (29.2) 100.9 (85.4–116.4)  
  1. mGPS modified glasgow prognostic score, PNI prognostic nutritional index, PLT platelet count, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
  2. aThe median survival for most groups was not arrived because most patients were still alive at the last follow-up. Therefore, survival data are presented as mean with the 95% confidence interval (CI) in parentheses
  3. bKaplan–Meier survival analysis
  4. cBefore 2005, CRP was not tested regularly in our center. Therefore, CRP data are not available for 90 patients, and we lacked associated data for mGPS